- Atlas
- Medicine & Health
- Pharmacodynamics
Pharmacodynamics
Pharmacodynamics is the branch of pharmacology that asks what a drug does to the body.
10 frameworks, from 100 to today · Pharmacology · Medicine & Health
- Materia medica 100-1820
- Experimental physiology and site-of-action pharmacology 1850-1930
- Receptor occupancy theory 1926-Present
- Pharmacological antagonism analysis 1937-Present
- Therapeutic index 1950-Present
- Pharmacogenomics 1955-Present
- Molecular target pharmacology 1960-Present
- Receptor theory 1980-Present
- Functional selectivity 1995-Present
- Quantitative systems pharmacology 2005-Present
Overview
Pharmacodynamics is the branch of pharmacology that asks what a drug does to the body12. Its core question is deceptively simple: how does a chemical substance produce a biological effect, and why does the same substance produce more effect at a higher dose, less at a lower one, and sometimes a different effect altogether in a different tissue or a different person? Where pharmacokinetics tracks what the body does to a drug—absorption, distribution, metabolism, excretion—pharmacodynamics tracks the reverse direction: the drug's action on its target, the chain of events that follows, and the relationship between the amount of drug present and the size of the response123.
That relationship is the field's central object. Practitioners want to know not merely that a drug works but how much effect follows from how much drug at the site of action, which molecular target mediates it, how selectively that target is hit, and why individual patients diverge. Each of those questions required a new experimental method, a new theory, or both, and the history of pharmacodynamics is largely the story of those methods and theories arriving.
Materia medica: remedies before mechanisms
For most of recorded history, the study of drugs was the study of materia medica—compendia of medicinal substances, their sources, preparations, and observed uses. The tradition is ancient and global: Chinese bencao literature, Ayurvedic works, Graeco-Roman herbals such as Dioscorides' De materia medica (first century CE), and the medieval Islamic and European compendia that transmitted and expanded them. These works recorded what a substance was thought to do, often in terms of humoral qualities—hot, cold, moist, dry—rather than molecular action4.
Materia medica was empirical and cumulative, and it was genuinely useful: it preserved knowledge of active plants such as opium, willow bark, and foxglove. But it could not answer why a remedy worked, could not separate the drug's action from the patient's expectation, and had no way to relate dose to effect except by rule of thumb. The decisive break came in the early nineteenth century, when chemists began isolating pure active principles—morphine from opium by Friedrich Sertürner around 1805, quinine from cinchona, strychnine, atropine—and physiologists began testing them on animals under controlled conditions. Once a drug was a defined chemical rather than a plant preparation, its effects could be measured and its dose varied systematically.
Experimental physiology and the search for the site of action
The founding move of modern pharmacodynamics was to ask where in the body a drug acts. In the mid-nineteenth century, experimental physiologists such as Claude Bernard and his contemporaries used isolated organs, nerve–muscle preparations, and animal experiments to localize drug effects. Bernard's demonstration that curare paralyses by acting on the junction between nerve and muscle—rather than on the nerve or the muscle itself—became a model for a new kind of reasoning: a drug's effect could be traced to a specific anatomical site, and the site could be identified by experiment.
This programme, often called the study of the "site of action," produced a wave of precise physiological pharmacology in the later nineteenth and early twentieth centuries. Oswald Schmiedeberg, working in Strasbourg, helped establish pharmacology as a laboratory science and a university discipline, and his students spread the experimental approach across Europe and North America. The questions became sharper: does a drug act on the heart directly or through nerves? Does it constrict vessels by acting on their muscle or on the nerve endings that supply them? The answer was found by comparing responses in intact animals, in isolated organs, and in denervated tissue.
Yet "site of action" remained a black box. Knowing that a drug acted on a particular organ did not explain why a tiny quantity could produce a large effect, or why chemically similar compounds produced very different effects.
Receptor theory: the idea of a specific target
The decisive theoretical step came from Paul Ehrlich and John Newport Langley at the turn of the twentieth century5. Ehrlich, working on chemotherapy and immunity, proposed that drugs and toxins bind to specific chemical structures in cells—"receptors"—in a lock-and-key fashion, and coined the idea of the magic bullet that would hit a disease target and nothing else. Langley, studying nicotine and curare on muscle, concluded independently that the drugs competed for a "receptive substance" in the tissue. Both men reached the same core idea from different directions: drug action is the binding of a molecule to a specific cellular constituent5.
The idea was powerful but qualitative. The next generation made it quantitative. In 1926, A. J. Clark, working at University College London, measured the response of isolated frog heart to acetylcholine and other drugs and found that the effect rose with concentration in a way that looked like a saturating binding curve. He proposed that the drug occupied receptors according to the law of mass action, and that the response was proportional to the fraction of receptors occupied. This is the origin of receptor occupancy theory: effect scales with how many receptors are filled, and the occupancy follows a hyperbolic relationship with drug concentration6.
Clark's model explained a great deal—why dose–response curves plateau, why a maximum effect exists, why potency differs between drugs—and it gave pharmacologists a mathematical language. But it had a conspicuous failure: some drugs produced a maximal response while occupying only a small fraction of receptors, and some occupied many receptors while producing little response. Occupancy alone could not account for differences in what came to be called efficacy or intrinsic activity1.
Antagonism, affinity, and the two-parameter drug
The 1930s and 1940s sorted this out. In 1937, Heinz Schild introduced a method for quantifying competitive antagonism: by measuring how much the agonist concentration must be raised to restore a given response in the presence of an antagonist, one can estimate the antagonist's affinity independently of the tissue. The Schild plot remains a standard tool for characterizing whether two drugs compete for the same receptor.
Meanwhile, E. J. Ariëns and R. P. Stephenson in the 1950s separated the two properties that a drug could have. Affinity is how tightly it binds the receptor; efficacy is how effectively bound receptors translate into response6. Ariëns spoke of intrinsic activity; Stephenson introduced the concept of "spare receptors"—tissue response can be maximal before all receptors are occupied, which explained the receptor reserve that had puzzled Clark's model. A drug with high affinity but zero efficacy became the definition of a competitive antagonist: it occupies the receptor without activating it, blocking agonists by exclusion7. This pharmacological antagonism analysis gave pharmacologists a way to classify drugs on two axes, affinity and efficacy, and to design experiments that distinguished competitive from non-competitive antagonism.
Selectivity and the therapeutic index
A parallel thread concerned not how a drug acts but how narrowly it acts. Ehrlich's magic bullet ideal implied that a useful drug should hit its intended target and spare others8. The practical measure of this is selectivity: the ratio between the concentration producing the desired effect and the concentration producing toxic effects—the therapeutic index9. The concept is old in spirit but was formalized in the mid-twentieth century as quantitative toxicology and pharmacology matured. Its history is less a single discovery than a gradual recognition that most drugs are not magic bullets: they bind many targets, and the art of drug design is often the art of widening the gap between benefit and harm. This idea became central as receptor subtypes were discovered—histamine H1 versus H2 receptors, adrenergic alpha versus beta receptors—each offering a chance to hit one effect and spare another.
Molecular target pharmacology and receptor subtypes
From the 1960s onward, pharmacology became molecular. The discovery of receptor subtypes, the development of radioligand binding assays (which allowed direct measurement of drug–receptor binding in tissue homogenates), and the purification and eventual cloning of receptors turned the receptor from a functional hypothesis into a physical molecule. By the 1980s and 1990s, receptors were being cloned and sequenced—the nicotinic acetylcholine receptor, the beta-adrenergic receptor, and many others—and their structures related to their drug-binding properties. Molecular target pharmacology became the dominant mode: identify the protein, understand its structure, find drugs that fit it, and measure the consequences.
This transformed drug discovery and also transformed pharmacodynamics itself. The question shifted from "what does this drug do to the tissue" to "which molecular target does it engage, with what affinity, and what downstream pathway follows."
Conformational states and the limits of occupancy
Cloning exposed a problem for the simple occupancy model. Many receptors, especially G-protein-coupled receptors, were found to have intrinsic activity even in the absence of agonist—constitutive activity—and some drugs reduced that activity rather than merely blocking agonists. These were inverse agonists, and they forced a revision: receptors exist in multiple conformational states, some active and some inactive, and drugs shift the equilibrium between them. An agonist stabilizes the active state, an inverse agonist stabilizes the inactive state, and a neutral antagonist binds without preference. Receptor theory and conformational states replaced the lock-and-key picture with a picture of a dynamic protein sampling different shapes.
Biased agonism and signal transduction
The most recent major turn came with the recognition that a single receptor can signal through more than one pathway, and that different drugs bound to the same receptor can favour different pathways10. This is biased agonism (or functional selectivity), documented in the late 1990s and 2000s. A drug that activates a receptor's G-protein pathway strongly but its beta-arrestin pathway weakly is "biased" toward one downstream effect10. The practical allure is obvious: if the therapeutic effect runs through one pathway and the side effects through another, a biased drug could separate them10. The concept has reshaped pharmacodynamics from a theory of occupancy and efficacy into a theory of signal transduction—of which intracellular cascades a drug-bound receptor engages, and how that choice can be steered11.
Pharmacogenetics and individual response
Running alongside the molecular story is the problem of why patients differ. The observation that some people respond to a drug and others do not, or suffer toxicity at ordinary doses, is old; the modern field of pharmacogenetics began in the 1950s with the recognition that inherited enzyme variants—for example, atypical pseudocholinesterase causing prolonged paralysis after succinylcholine, or glucose-6-phosphate dehydrogenase deficiency causing haemolysis with certain drugs—explained idiosyncratic reactions. Pharmacogenetics later grew into pharmacogenomics as genotyping became cheap and genome-wide. Its relevance to pharmacodynamics is direct: variation in the drug target itself, or in the signalling proteins downstream, changes the response to a given concentration12. A drug that works through a receptor polymorphic in the population may fail in some patients and over-respond in others.
Quantitative systems pharmacology: putting it back together
The newest strand is quantitative systems pharmacology (QSP), which emerged as a named discipline in the 2000s and 2010s. Its premise is that occupancy at a single receptor rarely explains a clinical effect; drugs act within networks of cells, tissues, and feedback loops, and the effect depends on the system as much as on the drug. QSP builds computational models that combine drug–target binding with the physiology of the disease—integrating pharmacodynamic parameters into mechanistic simulations of pathways, organs, and whole patients13. It is the descendant of both receptor theory and experimental physiology, now expressed in mathematical and computational form, and it is increasingly used in drug development to predict which doses and which targets are worth pursuing.
The present
Pharmacodynamics today is a layered discipline. At its base sits the quantitative receptor theory built by Clark, Schild, Ariëns, and Stephenson, refined by the conformational-state and biased-agonism models of the last three decades. Above it sits molecular target pharmacology, which identifies and characterizes the proteins drugs bind. Around it sits pharmacogenetics, explaining individual variation in target and pathway12. And increasingly it is being absorbed into systems pharmacology, which tries to model the whole network rather than the isolated receptor. The open questions are the ones the field has always faced, sharpened by new tools: how to predict efficacy from binding data, how to design drugs that are selective across a family of related targets, how to translate biased signalling into clinical benefit, and how to model a drug's effect in a patient whose network of pathways is not the same as the next patient's.
References
- Pharmacodynamics (introduction, Receptor binding and effect), Wikipedia
- Pharmacology, Wikipedia
- Pharmacokinetics, Wikipedia
- Clinical pharmacology (History), Wikipedia
- Receptor theory, Wikipedia
- Receptor (biochemistry) (Occupation), Wikipedia
- Receptor antagonist, Wikipedia
- Antineoplastic (History), Wikipedia
- Therapeutic index, Wikipedia
- Functional selectivity, Wikipedia
- Signal transduction, Wikipedia
- Pharmacogenomics, Wikipedia
- Quantitative systems pharmacology, Wikipedia
The frameworks of Pharmacodynamics
Each framework is a way of working the field has used: when it held, and the question it answers.
- 100-1820
- 1850-1930
Experimental physiology and site-of-action pharmacology
Where in the body does a drug act?
- 1926-Present
- 1937-Present
Pharmacological antagonism analysis
How do two drugs compete for one target?
- 1950-Present
- 1955-Present
- 1960-Present
- 1980-Present
- 1995-Present
- 2005-Present
Quantitative systems pharmacology
How can we predict a drug's whole-body effect?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Experimental physiology and site-of-action pharmacology replaced Materia medica
The isolation of pure alkaloids such as morphine by Sertürner around 1805 turned drugs from plant preparations into defined chemicals, and experimental physiologists like Claude Bernard then tested them on isolated organs to localize their sites of action. This experimental, mechanism-seeking programme displaced the humoral, compendium-based materia medica as the working approach to drug action.
Carried by Friedrich Sertürner; Claude Bernard; Oswald Schmiedeberg.
Receptor occupancy theory grew out of Experimental physiology and site-of-action pharmacology
The site-of-action programme localized drug effects to tissues but left the mechanism a black box; Ehrlich and Langley proposed that drugs bind specific cellular constituents, and A. J. Clark then measured acetylcholine responses on frog heart and modelled them as mass-action occupancy of those receptors. Receptor occupancy theory thus grew directly out of the experimental search for the site of action.
Carried by Paul Ehrlich; John Newport Langley; A. J. Clark.
Pharmacological antagonism analysis grew out of Receptor occupancy theory
Clark's occupancy model could not explain why some drugs occupy few receptors yet give maximal response; Schild's 1937 method for quantifying competitive antagonism and the later affinity/efficacy split by Ariëns and Stephenson refined the occupancy framework into a two-parameter analysis of agonism and antagonism. Antagonism analysis is a direct elaboration of receptor occupancy theory.
Carried by Heinz Schild; E. J. Ariëns; R. P. Stephenson.
Molecular target pharmacology influenced by Receptor occupancy theory
The receptor concept from occupancy theory gave molecular pharmacology its object of study; radioligand binding assays and receptor cloning turned the functional receptor of Clark into a physical protein. Molecular target pharmacology took the receptor hypothesis and made it structural and biochemical.
Carried by A. J. Clark; Paul Ehrlich.
Receptor theory grew out of Receptor occupancy theory
Later receptor theory generalized Clark's occupancy model, incorporating spare receptors, efficacy and eventually allosteric and operational models of agonism. It is a refinement of the same mass-action occupancy framework rather than a rejection of it.
Carried by R. P. Stephenson; E. J. Ariëns.
Receptor theory influenced by Pharmacological antagonism analysis
The affinity/efficacy distinction and the analysis of competitive antagonism developed in the 1930s–1950s supplied the conceptual vocabulary that later receptor theory formalized. Operational and two-state models of receptors build on the two-parameter drug description.
Carried by Heinz Schild; E. J. Ariëns; R. P. Stephenson.
Functional selectivity grew out of Molecular target pharmacology
Once receptors were cloned and their signalling pathways dissected, it became clear that a single receptor could activate multiple effectors; functional selectivity grew out of molecular target pharmacology as the recognition that ligands can bias signalling. It is a refinement of the molecular receptor framework.
Quantitative systems pharmacology grew out of Molecular target pharmacology
Quantitative systems pharmacology grew out of molecular target pharmacology by embedding identified drug targets in computational models of whole pathways and networks. It extends the molecular approach to predict system-level drug effects.
Functional selectivity grew out of Receptor theory
Functional selectivity extended receptor theory by showing that efficacy is not a single scalar but depends on which signalling pathway is measured. It is a generalization of the affinity/efficacy framework to pathway-specific agonism.
Molecular target pharmacology influenced by Pharmacological antagonism analysis
Schild analysis and the classification of competitive versus non-competitive antagonism provided the experimental logic that molecular pharmacologists later applied to defined receptor proteins. The method of quantifying drug–receptor interaction passed into the molecular era.
Carried by Heinz Schild.
Beyond the field
Where Pharmacodynamics's ideas came from in other fields, and what they led to there: the strongest 12 of 58 links.
Materia medica led to Pharmacology in Pharmacy
Pharmacology grew directly out of materia medica: the accumulated record of crude drugs and their effects was reorganised into a science of drug action by Buchheim and Schmiedeberg in the later nineteenth century. The earlier corpus supplied the substances and the empirical observations the new discipline systematised.
Carried by Rudolf Buchheim; Oswald Schmiedeberg.
Experimental physiology and site-of-action pharmacology led to Pharmacodynamics in Clinical Pharmacology
Site-of-action pharmacology, built on experimental physiology by Magendie, Bernard and Langley, is the direct parent of pharmacodynamics: it established that drugs act at specific bodily sites. Pharmacodynamics generalized this into the study of drug action mechanisms.
Carried by Claude Bernard; John Newport Langley.
Experimental physiology and site-of-action pharmacology influenced Pharmacology in Pharmacy
Experimental physiology, especially the work of Claude Bernard on curare and carbon monoxide, supplied the methods and the site-of-action concept that Schmiedeberg and his school built into pharmacology. The organ-and-receptor reasoning of the new discipline came from that physiological programme.
Carried by Claude Bernard; Oswald Schmiedeberg.
Receptor occupancy theory led to Two-Property Theory (Affinity and Efficacy) in Receptor Theory And Signal Transduction
Two-property theory arose as a refinement of occupancy theory: Ariëns and Stephenson kept occupancy but added intrinsic efficacy to explain why some occupiers produce little or no response.
Carried by Everhardus Jacobus Ariëns; Robert P. Stephenson.
Receptor occupancy theory influenced by Receptor theory in Cell Signaling
Receptor theory, as formulated by Ehrlich and Langley, supplied the concept of a specific receptive substance that occupancy theory then quantified with mass-action equations.
Carried by Paul Ehrlich; John Newport Langley.
Receptor occupancy theory influenced by Receptor theory in Pharmacology
Pharmacological receptor theory gave Clark the receptor concept he formalised as occupancy, making the later theory a quantitative refinement of it.
Carried by Alfred Joseph Clark.
Receptor occupancy theory led to Schild equation in Receptor Theory And Signal Transduction
The Schild equation extends occupancy theory to competitive antagonism, treating antagonist and agonist as competing for the same receptor sites under mass action.
Carried by Heinz Otto Schild.
Pharmacological antagonism analysis influenced by Receptor theory in Pharmacology
Receptor theory provided the concept of competitive binding at a receptive site that Gaddum and Schild formalised into the analysis of pharmacological antagonism.
Carried by John Henry Gaddum; Heinz Otto Schild.
Molecular target pharmacology grew out of Pharmacology in Pharmacy
Molecular target pharmacology grew out of classical pharmacology as the field turned from organ-level drug actions to identifying the specific macromolecules drugs bind. The receptor and enzyme work of earlier pharmacology supplied the targets and assay methods that the molecular approach took up.
Carried by Pharmacology.
Molecular target pharmacology influenced Targeted therapy in Medicinal Chemistry
Molecular target pharmacology supplied the concept of a defined molecular target whose blockade produces therapeutic effect, the premise on which targeted therapy rests.
Receptor theory grew out of Two-Property Theory (Affinity and Efficacy) in Receptor Theory And Signal Transduction
The two-property theory of affinity and efficacy, associated with Stephenson and Ariëns, separated binding from activation and became the core of modern receptor theory. Later receptor models refined this distinction rather than replacing it.
Carried by E. J. Ariëns; R. P. Stephenson.
Receptor theory grew out of Occupancy Theory in Receptor Theory And Signal Transduction
Occupancy theory, formalized by Clark and later Gaddum, held that drug effect is proportional to the fraction of receptors occupied. Modern receptor theory grew directly from it, adding efficacy and spare receptors to correct its shortcomings.
Carried by Alfred Joseph Clark.

Pharmacodynamics is a planet in Nousfarer
Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.
Land on PharmacodynamicsRelated fields
Fields its ideas are linked to
- Pharmacology 11 links
- Receptor Theory And Signal Transduction 9 links
- Medicinal Chemistry 5 links
- Pharmacognosy 4 links
- Pharmacy 4 links
- Psychopharmacology 3 links
- Drug Discovery 3 links
- Cell Signaling 2 links
- Physiology 2 links
- Clinical Pharmacology 2 links
- Pharmacometrics 2 links
- Toxicology 2 links
More in Pharmacology
- Clinical Pharmacology
- Drug Discovery
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- Pharmacometrics
- Pharmacovigilance
- Receptor Theory And Signal Transduction
- Toxicology
- Translational Pharmacology
See where Pharmacodynamics sits on the Map of Human Knowledge